NCT05155332 2026-03-17
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
Clinical Trials
9 trialsNCT06892379 2026-03-13
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT04261413 2026-03-11
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
Phase 1 Completed
NCT03313778 2026-03-04
KEYNOTE-603
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT03448042 2026-02-27
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Phase 1 Active not recruiting
NCT07176975 2026-02-27
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
Phase 1 Not yet recruiting
NCT07030959 2026-02-25
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
Phase 1 Recruiting
NCT04250155 2026-02-24
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Active not recruiting
NCT07181681 2026-02-23
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting